Cargando…
Safety, Tolerability, and Pharmacokinetics of FAAH Inhibitor BIA 10‐2474: A Double‐Blind, Randomized, Placebo‐Controlled Study in Healthy Volunteers
This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of BIA 10‐2474, a fatty acid amide hydrolase (FAAH) inhibitor, after first administration to healthy male and female participants. Participants (n = 116) were recruited into this phase I, double‐blind, randomized,...
Autores principales: | Rocha, José‐Francisco, Santos, Ana, Gama, Helena, Moser, Paul, Falcão, Amílcar, Pressman, Peter, Wallace Hayes, A., Soares‐da‐Silva, Patricio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292215/ https://www.ncbi.nlm.nih.gov/pubmed/33998672 http://dx.doi.org/10.1002/cpt.2290 |
Ejemplares similares
-
Preclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 10‐2474
por: Bonifácio, Maria‐João, et al.
Publicado: (2020) -
Effect of Food on the Pharmacokinetic Profile of Etamicastat (BIA 5-453)
por: Vaz-da-Silva, Manuel, et al.
Publicado: (2012) -
Discovery of a Potent, Long‐Acting, and CNS‐Active Inhibitor (BIA 10‐2474) of Fatty Acid Amide Hydrolase
por: Kiss, László E., et al.
Publicado: (2018) -
Safety, Tolerability and Pharmacokinetics of FAAH Inhibitor V158866: A Double-Blind, Randomised, Placebo-Controlled Phase I Study in Healthy Volunteers
por: Pawsey, Stephen, et al.
Publicado: (2016) -
What failed BIA 10–2474 Phase I clinical trial? Global speculations and recommendations for future Phase I trials
por: Kaur, Rimplejeet, et al.
Publicado: (2016)